Академический Документы
Профессиональный Документы
Культура Документы
The pharmerging markets including Brazil, Russia, Mexico , Turkey, India, China and others are expected to register a CAGR of 12-15 % over 2012-16 , slightly lower than that of the previous period (2008-12 ).
The year 2012 closed with a growth of 12%, lower than the previous year's growth of 16%, according to data culled from research
firm IMS Health. Overall, IMS has forecast that the pharma market will grow at a CAGR of 13.7% between 2011 and 2016, with this year's growth pegged between 11-15 %. Total spending on healthcare , which accounted for 4.1% of GDP in 2010, will continue to increase at double-digit rates, driven by a combination of rising incomes and a commitment to raise levels of public funding for the sector,
Global Respiratory scenario The global respiratory therapeutics market was valued at $30.1 billion in 2010 and is expected to grow to $37.4 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 3.1%.
In 2010, approximately 49 million patients received pharmacological treatment for respiratory disorders with the annual cost of therapy being $611 per year.
In addition, the annual cost of therapy for the respiratory disorders therapeutic area is expected to increase at a gradual rate over the following year.
The prescription respiratory world market value is Therapy area world market (MAT/Q3/11) ($bn)
$64.6 billion
The drivers hence gives an opportunity for growth in the market whereas the restraints can be worked in to fill the gaps
Most of the 250,000 deaths from asthma each year can be attributed to lack of proper treatment.
Although COPD will be the 3rd leading cause of death worldwide by 2020, it is frequently not diagnosed;
Six states (Kerala, AP, HP, UP, Karnataka and WB) account for more than 68 percent of the acute respiratory burden with Kerala topping the list Asthma, COPD and pneumonia are the leading causes of hospitalization among patients with respiratory disorders
Respiratory agents is the 6th largest therapeutic class Respiratory growth is constantly higher than the market reflecting a growing potential
Respiratory agents are expected to remain the third-biggest seller, with a $5 billion to $10 billion
http://www.forbes.com/sites/matthewherper/2012/07/12/the-global-drug-market-willswell-to-1-2-trillion-while-big-pharma-treads-water/
1 2 3 4 5 6
AstraZeneca
Gastrointestinal disorders Otsuka Pharmaceutical, Bristol-Myers Psychosis, Squibb Depression AstraZeneca, Shionogi Cholesterol Eli Lilly and Company Abbott Laboratories GlaxoSmithKline Depression, Anxiety disorders Rheumatoid arthritis Asthma
Cymbalta Duloxetine Humira Advair Diskus, Seretide Enbrel Adalimumab Fluticasone + Salmeterol Etanercept
7 8
1,066,697 952,068
12.51% 2.02%
Amgen
Remicade Infliximab
9 10
14 23
877,591 832,784
669,882 486,837
9.93% -1.17%
1.31% -62.20%
Filgrastim
Tiotropium Montelukast
Rheumatoid arthritis Johnson & Johnson, Merck & Co., Inc., Crohn's disease, Mitsubishi Tanabe Pharma Rheumatoid arthritis Teva Pharmaceutical Industries, Sanofi- Multiple sclerosis Aventis Amgen Neutropenia
Boehringer Ingelheim Merck & Co. Chronic obstructive pulmonary disease Asthma
Prodouct
Advair Diskus
Molecule
Fluticasone propionate+salmeterol inh
Manufacturer
GSK
2
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Singulair
Spiriva Handihaler Symbicort Combivent ProAir HFA Nasonex Flovent HFA Budenoside Ventolin HFA Xolair Fluticasone propionate Pulmozyme Qvar Advair HFA Xopenex Tobi Revatio montelukast sodium Pataday Proventil HFA Asmanex twisthaler Pulmicort respules Atrovent HFA Patanol
Montelukast sodium
tiotropium bromide budenoside+formoterol albuterol sulphate inhalent momentasone furoate Fluticasone propionate albuterol sulphate inhalent omalizumab dornase alpha beclamethasone dipropionate Fluticasone propionate+ salmeterol levosalbutamol Tobramycin sidenafil citrate olopatadine albuterol sulphate inhalent momentasone furoate inhalation powder budenoside inhalation suspension inhalation aerosol
Merk
Boehringer Ingelheim Astra Zeneca Teva Merk GSK Generic GSK Genetech/Novartis Generic Genetech Teva GSK Sunovion Novartis Pfizer Generic Alcon Merk Merk Astra Zeneca Alcon
$3299.7
$2832.1 $ 1299.99 $1139.0 $ 1122.6 $ 1107.6 $1038.0 $ 944.4 $ 714.7 $ 707.4 $ 525.9 $ 458.2 $ 423.1 $ 362.4 $ 336.5 $332.1 $ 323.8 $300.2 $ 299.1 $ 230.9 $227.5 $222.9 $ 212.0 $211.1
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
Dulera Albuterol Brovana Veramyst Azelastine HCL Xopenex HFA Astepro Clarinex Triaminoclone Pulmicort flexhalers Patanase levabuterol hydrochloride Perforomist Serevent Diskus Albuterol sulphate/ipratropium Adcirca
momentasaone furoate+ formeterol arformeterol tartarate solution Fluticasone furoate levabuterol tablets azelastine desloratidinetablets/ oral soution budenoside inhalation suspension olopatadine hydrochloride formoterol fumarate salmeterol xinafolate powder tadalafil tablets
Merk Generic sunovion GSK Generic Sunovion Meda Merk Generic Astra Zeneca Alcon Generic Dey GSK Generic Lung LLC
$ 209.2 $188.0 $173.0 $141.4 $141.3 $ 140.2 $126.2 $121.3 $116.2 $116.0 $109.8 $108.6 $98.8 $86.0 $82.4 $77.5
42
43 44 45 46 47 48 49 50
Daliresp
Foradil Aeroliise Ipratropium bromide Rhinocort Aqua Flovent Diskus Zyflo CR Alvesco Levocetrizine dih Alrex
rofulimast
formoterol fumarate budenoside inhaler fluticasone propionate Zileuton ciclesonide inhalation aerosol oteprednol
Forest
Merk Generic Astra Zeneca GSK Cornerstone Sunovion Generic Bausch&Lomb
$71.4
$68.6 $63.5 $60.2 $58.5 $56.9 $54.9 $48 $45.4
Lung Surfactants
ILD,ILF,Sarcoidosis
Upper (Common cold, Sinusitosis, Pharyngitis, Tonsillitis, ear infection, Laryngitis Lower- Bronchitis, Pneumonia, TN Otitis media
Anti-histamines, Cold & Cough, Antibiotics
Malignant, Benign
Lung Surfactants
Infant RDS
Upper (Common cold, Sinusitosis, Pharyngitis, Tonsillitis, ear infection, Laryngitis Lower- Bronchitis, Pneumonia, TN Otitis media
Anti-histamines, Cold & Cough, Antibiotics
Malignant, Benign
Lung surfactant
Anti asthma
Sys Corticosteroid s
Val - 4655 mio ; Gr 10% ; CAGR13%
Asthma medication
Controllers Steroids, LABA, Theophylline, Leukotriene receptor antagonist,cromones
Beclomethasone,Budenoside,
Fluticasone Source: GINA guidelines
Mild Asthmatics
LABA or patient dependent treatment low dose inhaled ICS Leukotriene modifiers
Moderate Asthmatics
Low dose ICS+LABA medium or high dose ICS low dose ICS+ leukotriene modifier low dose ICS plus sustained release theophylline High dose ICSLABA LTRA Theophylline oral steroids Anti- IgE treatment
Severe Asthmatics
India also contributes a significant and growing percentage of COPD mortality estimated to be amongst the highest in the world; i.e. more than 64.7 estimated age standardized death rate per 100,000 amongst both sexes as mentioned in the WHO Global Infobase Updated on 20th January 2011 (India 102.3 and China 131.5).
This would translate into approximately 556,000 in case of India (>20%) and 1,354,000 cases in China (about 50%) out of a world total of 2,748,000 annually
Though Asthma is prevalent, It can be seen that the burden of COPD Is increasing proportionately.
1st Choice
Ipratropium
2nd Choice
Tiotropium OR Salmeterol / Formoterol OR Ipratropium + Levosalbutamol
Alternative
Doxophylline
GOLD 1 or 2 OR Exacerbation 1/yr Levosalbutamol mMRC 0-1 CAT score < 10 Low risk More Symptoms
Tiotropium + Salmeterol / Formoterol ICS + Tiotropium OR ICS + Salmeterol / Formoterol + Tiotropium OR ICS + Salmeterol / Formoterol + Roflumilast OR Tiotropium + Roflumilast
It is forecasted that by 2019 the asthma patients(drug treated) will increase from 31% to 32.4% whereas that of COPD is expected to rise 17.9% in 2009 to 23.9%.
Molecules Of potential
Olopatadine Currently, these molecules have not been launched Top global molecules In India for currently indication of COPD not in and asthma but India occupy a space in the global top 50 Loteprednol Respiratory products
Dornase
alpha
Rofulimast
Zileuton
More than 50 drugs are in pipeline which avails a bigger market in future.
IbudilastPD4 inhibitor
Bedoradrin e-SABA
Vilanter olLABA
Summary
Asthma and COPD incidences will be on the rise in India and these markets will be the
Anti-biotics forte. Ranbaxy is ranked low in antihistamines and has virtually no presence in the high value cough and cold market
New products are driving growth in the respiratory market Cipla maintains its No 1 position in the bronchodilator inhalation market and Lupin is
No 2
Bronchodilator & Antiasthma solids market has shown a revival in the past few years